Back to top
more

Agenus (AGEN)

(Delayed Data from NSDQ)

$10.78 USD

10.78
356,061

+0.08 (0.75%)

Updated May 15, 2024 04:00 PM ET

After-Market: $10.74 -0.04 (-0.37%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

What's in Store for Agenus (AGEN) this Earnings Season?

Agenus Inc. (AGEN) is expected to report first-quarter 2017 results later this month or early next month.

    Why Is Agenus (AGEN) Down 16.8% Since the Last Earnings Report?

    Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

      Agenus (AGEN) Sharpens Focus on Drug Development Programs

      We issued an updated report on Agenus Inc. (AGEN) on Apr 4.

        Agenus (AGEN) Reports Narrower-than-Expected Loss in Q4

        Agenus Inc. (AGEN) reported fourth-quarter 2016 loss of 30 cents per share (including non-cash expenses), narrower than the Zacks Consensus Estimate of a loss of 33 cents but wider than the year-ago loss of 18 cents.

          Agenus (AGEN) Reports Narrower-than-Expected Q4 Loss

          Agenus reported narrower-than-expected loss in the fourth quarter of 2016. Our consensus called for a loss of 33 cents per share, while the company reported a loss of 30 cents.

            Agenus (AGEN): What's Ahead for the Stock in Q4 Earnings?

            Agenus Inc. (AGEN) is expected to report fourth-quarter 2016 results during this month.

              Agenus, NCI Ink Deal to Evaluate Prophage-Keytruda Combo

              Agenus (AGEN) entered into a clinical trial collaboration with the National Cancer Institute to evaluate Prophage, in conjunction with Merck's (MRK) Keytruda.

                Agenus' INCAGN1876 in Phase I/II Study for Solid Tumors

                Agenus (AGEN) announced that it has dosed the first patient in a phase I/II study on INCAGN1949 for the treatment of patients with solid tumors.